Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Expert Opinion on Drug Delivery|September 29, 2021
Safety of recombinant human hyaluronidase PH20 for subcutaneous drug deliveryStephen P Knowles, Marie A Printz, David W Kang, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 1, 2024
The safety of recombinant human hyaluronidase PH20 in nonclinical models: An overview of toxicology, pharmacology, and impact of anti-PH20 antibodiesRyan P Nolan, David W Kang, Daniel C Maneval, et al.
Wound Repair and Regeneration : Official Publication of the Wound Healing Society [And] the European Tissue Repair Society|September 24, 2005
Recombinant adenovirus-p21 attenuates proliferative responses associated with excessive scarringDanling Gu, Isabella Atencio, David W Kang, et al.
Drug Delivery and Translational Research|May 30, 2025
A phase I clinical study to evaluate rapid, high-volume, subcutaneous auto-injector tolerability with recombinant human hyaluronidaseDavid W Kang, Robert J Connor, Tara Nekoroski, et al.
Bioconjugate Chemistry|November 18, 2004
Synthetic biocompatible cyclodextrin-based constructs for local gene delivery to improve cutaneous wound healingNathalie C Bellocq, David W Kang, Xuehui Wang, et al.
Drug Delivery and Translational Research|May 22, 2026
Enhanced subcutaneous delivery of antibody-drug conjugates with recombinant human hyaluronidase PH20: pharmacokinetics and tolerability in minipigsRyan P Nolan, Robert J Connor, Marie A Printz, et al.
The AAPS Journal|October 20, 2022
Risk Factors, Hyaluronidase Expression, and Clinical Immunogenicity of Recombinant Human Hyaluronidase PH20, an Enzyme Enabling Subcutaneous Drug AdministrationMarie A Printz, Barry J Sugarman, Rudolph D Paladini, et al.
Current Therapeutic Research, Clinical and Experimental|September 23, 2020
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy VolunteersMarie A Printz, Samuel S Dychter, Emanuel P DeNoia, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|October 27, 2019
Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in ratsIan K Styles, Orlagh M Feeney, Tri-Hung Nguyen, et al.
Nanomedicine (London, England)|February 9, 2021
Depolymerization of hyaluronan using PEGylated human recombinant hyaluronidase promotes nanoparticle tumor penetrationDaniel Hs Brundel, Orlagh M Feeney, Cameron J Nowell, et al.
Pageof 3